Enteralia Bioscience SRL ("Enteralia") is pleased to announce the acquisition of TFarma, a well-established company focused on the sales and marketing of nutraceuticals and medical devices in Italy. This strategic acquisition marks a key milestone in Enteralia's expansion within the Italian market, one of Europe's largest and most influential sectors.
Through this acquisition, Enteralia gains direct access to an established network of over 20 Medical Representatives and Area Managers, who are known for their expertise in the gynecological and gastroenterological fields. The integration of TFarma's product portfolio, which has a strong and consistent revenue track record, will further bolster Enteralia's growth trajectory.
Looking ahead, Enteralia plans to expand its sales network and territorial reach, supported by the introduction of new products from the pipeline of Nemysis Limited, its parent company. These investments are expected to drive substantial revenue and profit growth in the near term.
In addition to expanding the product portfolio, Enteralia is committed to investing in TFarma's existing team, recognizing the critical role they play in the company's success.
"We are delighted to welcome TFarma and its team into the Enteralia family, accelerating our future growth and strengthening our position in the Italian market. The synergy between our product lines, and the experience of TFarma's team, reinforce our strategy and ability to accomplish increasingly ambitious growth" said Antonio Maggi, CEO of Enteralia Bioscience SRL.
Dr. Claudio Ciani and Dr. Giuseppe Giuliani, founding partners of TFarma, shared, "After nearly 20 years since TFarma's founding, we are excited to join Enteralia and its team as we enter a new phase of growth. Our shared focus on women's health and gastroenterology, combined with Enteralia's significant investment in our team and new products from their pipeline, makes Enteralia an ideal partner for our future."
About Enteralia Bioscience SRL
Enteralia Bioscience SRL is an Italian pharmaceutical company and part of the Nemysis Limited group. Its mission is to promote innovative research products from Nemysis, targeting professionals in gynecology and gastroenterology. Enteralia aims to provide effective solutions for prevalent health issues, including iron deficiency, with or without anemia.
About TFarma
TFarma SRL is an Italian pharmaceutical company with a 20-year presence in the gynecological and gastroenterological therapeutic areas. Known for its innovative and effective solutions, TFarma focuses on products that enhance women's health and manage gastroenterological disorders.
SOURCE: Enteralia Bioscience Srl
View the original press release on newswire.com.
Transmitted by IRW-Press a News Service of IR-WORLD.com Finanzkommunikation GmbH
The author of the news release is solely responsible for the content of the release or research. This news does not constitute investment advice or an invitation to conclude certain stock exchange transactions.
Through this acquisition, Enteralia gains direct access to an established network of over 20 Medical Representatives and Area Managers, who are known for their expertise in the gynecological and gastroenterological fields. The integration of TFarma's product portfolio, which has a strong and consistent revenue track record, will further bolster Enteralia's growth trajectory.
Looking ahead, Enteralia plans to expand its sales network and territorial reach, supported by the introduction of new products from the pipeline of Nemysis Limited, its parent company. These investments are expected to drive substantial revenue and profit growth in the near term.
In addition to expanding the product portfolio, Enteralia is committed to investing in TFarma's existing team, recognizing the critical role they play in the company's success.
"We are delighted to welcome TFarma and its team into the Enteralia family, accelerating our future growth and strengthening our position in the Italian market. The synergy between our product lines, and the experience of TFarma's team, reinforce our strategy and ability to accomplish increasingly ambitious growth" said Antonio Maggi, CEO of Enteralia Bioscience SRL.
Dr. Claudio Ciani and Dr. Giuseppe Giuliani, founding partners of TFarma, shared, "After nearly 20 years since TFarma's founding, we are excited to join Enteralia and its team as we enter a new phase of growth. Our shared focus on women's health and gastroenterology, combined with Enteralia's significant investment in our team and new products from their pipeline, makes Enteralia an ideal partner for our future."
About Enteralia Bioscience SRL
Enteralia Bioscience SRL is an Italian pharmaceutical company and part of the Nemysis Limited group. Its mission is to promote innovative research products from Nemysis, targeting professionals in gynecology and gastroenterology. Enteralia aims to provide effective solutions for prevalent health issues, including iron deficiency, with or without anemia.
About TFarma
TFarma SRL is an Italian pharmaceutical company with a 20-year presence in the gynecological and gastroenterological therapeutic areas. Known for its innovative and effective solutions, TFarma focuses on products that enhance women's health and manage gastroenterological disorders.
SOURCE: Enteralia Bioscience Srl
View the original press release on newswire.com.
Transmitted by IRW-Press a News Service of IR-WORLD.com Finanzkommunikation GmbH
The author of the news release is solely responsible for the content of the release or research. This news does not constitute investment advice or an invitation to conclude certain stock exchange transactions.
